Oxaliplatin degradation in the presence of important biological sulphur-containing compounds and plasma ultrafiltrate

European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
Elin JerremalmHans Ehrsson

Abstract

Oxaliplatin undergoes extensive non-enzymatic chemical transformation in the body. Complexes with sulphur-containing compounds have previously been found in plasma from patients treated with oxaliplatin. We have studied the kinetics for the reactions between oxaliplatin and cysteine, methionine, and glutathione, by determination of the degradation of oxaliplatin using liquid chromatography with UV-detection. We also studied the degradation of oxaliplatin in plasma ultrafiltrate (PUF). For the degradation of oxaliplatin in the presence of glutathione, methionine, and cysteine, the second-order rate constants were 4.7M(-1)min(-1) (95% confidence interval [C.I.], 4.4-5.0M(-1)min(-1)), 5.5M(-1)min(-1) (95% C.I., 5.2-5.7M(-1)min(-1)), and 15M(-1)min(-1) (95% C.I., 14-17M(-1)min(-1)), respectively. The reaction rate was much faster than previously reported kinetics for cisplatin. The degradation rate of oxaliplatin in PUF was biphasic. The rate constant for the first phase varied from 9.5x10(-3) to 0.13min(-1) and for the second phase from (1.7 to 1.8)x10(-3)min(-1) in PUF from five healthy volunteers. The first hours of the degradation of oxaliplatin in PUF are accounted for by the degradation of oxaliplatin in a cocktail of sodium ...Continue Reading

References

Mar 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·W A Abbott, A Meister
Nov 27, 1985·Biochemical and Biophysical Research Communications·J L ButourJ P Macquet
Aug 1, 1996·Journal of Pharmaceutical Sciences·A AnderssonH Ehrsson
Sep 1, 1996·The Journal of Pharmacy and Pharmacology·N NagaiH Ogata
Feb 21, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T PainbeniP Allain
Mar 31, 1999·Journal of Biochemical and Molecular Toxicology·F R LuoS G Chaney
May 16, 2000·Biochemical Pharmacology·W A Kleinman, J P Richie
Jun 23, 2000·Drugs·I Judson, L R Kelland
Oct 3, 2001·Clinica Chimica Acta; International Journal of Clinical Chemistry·H OnoN Sakura
Mar 21, 2002·Cancer Investigation·Sridhar ManiStephen G Chaney
Jun 27, 2002·Biochimica Et Biophysica Acta·Barbara A Woynarowska, Jan M Woynarowski
Sep 13, 2002·Journal of Pharmaceutical Sciences·Elin JerremalmHans Ehrsson
Oct 9, 2002·Mini Reviews in Medicinal Chemistry·Rathindra N Bose
Jan 2, 2003·The Journal of Biological Chemistry·Aleksandra MandicMaria C Shoshan
Jan 7, 2003·Medical Oncology·H EhrssonJ Yachnin
Apr 25, 2003·Journal of Pharmaceutical Sciences·Miranda VerschraagenWim J F Van der Vijgh
Oct 3, 2003·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Hans Ehrsson, Inger Wallin
Nov 12, 2003·The Journal of Pharmacology and Experimental Therapeutics·Douglas HagrmanAbdul-Kader Souid
Dec 19, 2003·Free Radical Biology & Medicine·Siobhan E MoriartyPaul Sternberg
Aug 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chris H TakimotoJean L Grem

❮ Previous
Next ❯

Citations

Jun 20, 2008·European Journal of Clinical Pharmacology·H MahtemeH Ehrsson
Jan 1, 2009·Journal of the National Cancer Institute·Victoria HellbergGöran Laurell
Jan 14, 2009·Journal of Negative Results in Biomedicine·Amir BroomandFredrik Elinder
Mar 16, 2013·Journal of Gastrointestinal Cancer·Fatima Zahra HijriOmar El Mesbahi
Apr 3, 2009·Journal of Pharmaceutical Sciences·Elin JerremalmHans Ehrsson
Jan 31, 2012·Biochemical Pharmacology·Maria E Palm-Espling, Pernilla Wittung-Stafshede
Aug 13, 2009·Advanced Drug Delivery Reviews·David P Nowotnik, Esteban Cvitkovic
May 29, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Miriam KoopmanCornelis J Punt
Jul 24, 2010·The American Journal of Pathology·Hans Ehrsson, Inger Wallin
Aug 27, 2014·Frontiers in Pharmacology·Emma E Ramsay, Pierre J Dilda
Nov 2, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Filipa Lopes-CoelhoJacinta Serpa
Dec 6, 2016·Scientific Reports·Xin Liu, Amanda B Hummon
Feb 20, 2017·Journal of Inorganic Biochemistry·Shu Xian ChongKenneth Kin Wah To
Sep 25, 2015·The Biochemical Journal·Linhong ZhaoYangzhong Liu
Jul 21, 2012·Metallomics : Integrated Biometal Science·Shaoyu WangJanice R Aldrich-Wright

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
Hans Ehrsson, Inger Wallin
Cellular and Molecular Life Sciences : CMLS
A M Di FrancescoR Riccardi
© 2022 Meta ULC. All rights reserved